Equity Overview
Price & Market Data
Price: $11.65
Daily Change: -$0.02 / 0.17%
Daily Range: $11.65 - $11.65
Market Cap: $390,062,752
Daily Volume: 106
Performance Metrics
1 Week: -24.66%
1 Month: -10.71%
3 Months: 7.86%
6 Months: 6.77%
1 Year: -50.23%
YTD: -36.68%
Company Details
Employees: 43
Sector: Health technology
Industry: Biotechnology
Country:
Details
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.